Clinical Trial

Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis

Completed
View on ClinicalTrials.gov →
Summary
The goals of this observational study are to investigate the role of myeloid-derived suppressor cells (MDSCs) in fueling chronic inflammation that is a relevant pathogenetic mechanism in patients with primary myelofibrosis (PMF), to study modifications in MDSC phenotype and function after treatment with JAK-inhibitors (JAK-i) and to test their participation in the neoangiogenic process. The main questions it aims to answer are: * Do the frequency and function of MDSCs contribute to induce or sustain the inflammatory status that characterizes PMF? * Does the number of circulating MDSCs in PMF patients correlate with clinical/biological parameters? * Are MDSCs involved in the neoangiogenic processes that characterizes PMF?
Trial Details
NCT Number NCT07319026
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions Primary Myelofibrosis (PMF), Healthy Subjects
Enrollment 70 participants
Start Date 2023-11-14
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-06